A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection

Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Borte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Soc Nephrol
Autors principals: Eskandary, Farsad, Regele, Heinz, Baumann, Lukas, Bond, Gregor, Kozakowski, Nicolas, Wahrmann, Markus, Hidalgo, Luis G., Haslacher, Helmuth, Kaltenecker, Christopher C., Aretin, Marie-Bernadette, Oberbauer, Rainer, Posch, Martin, Staudenherz, Anton, Handisurya, Ammon, Reeve, Jeff, Halloran, Philip F., Böhmig, Georg A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2018
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791086/
https://ncbi.nlm.nih.gov/pubmed/29242250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2017070818
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars